The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AEROVATE THERAPEUTICS INC | COM | 008064107 | 4,583 | 276,447 | SH | OTR | 1 | 0 | 276,447 | 0 | |
| ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 22,006 | 3,056,420 | SH | OTR | 1 | 0 | 3,056,420 | 0 | |
| BELLUS HEALTH INC NEW | COM NEW | 07987C204 | 25,155 | 2,382,127 | SH | OTR | 1 | 0 | 2,382,127 | 0 | |
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 8,140 | 2,325,833 | SH | OTR | 1 | 0 | 2,325,833 | 0 | |
| IMMUNIC INC | COM | 4525EP101 | 3,388 | 1,072,288 | SH | OTR | 1 | 0 | 1,072,288 | 0 | |
| KINNATE BIOPHARMA INC | COM | 49705R105 | 20,012 | 1,674,677 | SH | OTR | 1 | 0 | 1,674,677 | 0 | |
| MERUS N V | COM | N5749R100 | 12,280 | 613,071 | SH | OTR | 1 | 0 | 613,071 | 0 | |
| OTONOMY INC | COM | 68906L105 | 682 | 2,312,880 | SH | OTR | 1 | 0 | 2,312,880 | 0 | |
| PARDES BIOSCIENCES INC | COM | 69945Q105 | 4,210 | 2,275,732 | SH | OTR | 1 | 0 | 2,275,732 | 0 | |
| PASSAGE BIO INC | COM | 702712100 | 3,441 | 2,752,422 | SH | OTR | 1 | 0 | 2,752,422 | 0 | |
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 4,042 | 3,515,140 | SH | OTR | 1 | 0 | 3,515,140 | 0 | |
| THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 2,928 | 504,862 | SH | OTR | 1 | 0 | 504,862 | 0 | |